Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Dose Adjusted Apixaban for the Treatment of Venous Thromboembolism in Cancer Patients with Thrombocytopenia, ADAPTiON Trial

Trial Status: active

This early phase I trial tests the safety and side effects of dose adjusted apixaban and how well it works in treating blood clots (venous thromboembolism) in cancer patients with a low number of platelets (thrombocytopenia). Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism and those with thrombocytopenia are at a high risk of developing major bleeding, making treatment challenging. Treatment usually includes drugs that are given by injection to prevent or reduce blood clot formation (anticoagulation), with platelet transfusion support as needed. Apixaban is an oral drug that blocks the action of coagulation factor Xa and may prevent blood clots from forming and may treat blood clots that have already formed. The dose of apixaban will be adjusted based on the number of platelets and perceived risk of bleeding. Giving dose adjusted apixaban may be safe, tolerable, and/or effective in treating venous thromboembolism and preventing bleeding events in cancer patients with thrombocytopenia.